Cell Response and Regulation (CRR)

细胞反应与调节 (CRR)

基本信息

批准号：
10152544
负责人：
Trudy Gale Oliver
金额：
$ 6.62万
依托单位：
UNIVERSITY OF UTAH
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-05-09 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10152544
关键词：
Address American Cancer Society Area Award Back Basic Science Cancer Biology Cancer Center Cancer Center Support Grant Cancer Control Cancer Model Cause of Death Cell Cycle Stage Cell Death Cell Fate Control Cell Proliferation Cells Cellular biology Clinic Clinical Collaborations Department of Defense Development Diagnostic Disease Disseminated Malignant Neoplasm Distant Doctor of Philosophy Drosophila genus Drug Targeting Education Effectiveness Embryo Environment Fostering Foundations Funding Genetically Engineered Mouse Goals Grant Human Infrastructure Institutes Investigation Investigational Therapies Journals Malignant Neoplasms Mediating Metastatic to Mission Modeling Neoplasm Metastasis Organoids Paper Pathway interactions Patients Peer Review Peer Review Grants Population Population Sciences Pre-Clinical Model Prevention Principal Investigator Publications Publishing Regulation Research Research Personnel Resistance Resource Sharing Safety Schools Science Scientist Signal Pathway Signal Transduction Signaling Molecule Site Solid Neoplasm Strategic Planning Sushi Domain System Testing Training Translating United States National Institutes of Health Universities Utah Work Xenopus Zebrafish biomarker development cancer cell cancer prevention cancer therapy cell motility college insight interdisciplinary collaboration investigator-initiated trial malignant state member mouse model neoplastic cell next generation novel novel strategies novel therapeutics patient derived xenograft model patient oriented research prognostic programs response self-renewal stem stem cells success therapy development therapy resistant translational pipeline tumor tumorigenesis

项目摘要

CELL RESPONSE AND REGULATION PROGRAM ABSTRACT The Cell Response and Regulation (CRR) Program is a basic science program at Huntsman Cancer Institute (HCI). CRR discovery science supports the Center’s mission “to understand cancer from its beginnings” by gaining new insight into basic mechanisms of cancer biology and providing a foundation for addressing critical clinical issues according to HCI’s strategic plan. CRR members use scientific ingenuity and the extensive Shared Resources provided by HCI to make new discoveries, and they collaborate with members of the Cancer Control and Population Sciences Program and the Experimental Therapeutics Program to translate these discoveries to the clinic and population in the areas of cancer prevention, target identification, biomarker development, prognostics, diagnostics, and treatment development. CRR research is centered on the following Specific Aims: 1) to elucidate mechanisms underlying cell proliferation, differentiation, and survival; 2) to uncover mechanisms and pathways mediating tumor metastasis; and 3) to understand tumor development and response to therapy. CRR is comprised of 37 members, representing 15 academic departments and four schools/colleges at the University of Utah. CRR members are well-funded, with $8.2M in peer-reviewed grant funding, of which $3.0M (33%) is from the NCI. The remainder of the peer-reviewed funding portfolio includes grants focused on cellular cancer mechanisms from the National Institutes of Health, the Department of Defense, Susan G. Komen Foundation, and the American Cancer Society. Ninety-three percent of full members have current, peer- reviewed, cancer-focused funding. In the current funding cycle, CRR members published 266 cancer-focused papers; 14% of these represent intra-programmatic collaborations, and 41% stem from inter-programmatic collaborations. The synergistic aims of the CRR Program create a highly productive, collaborative, and impactful research environment that is bolstered by the organizational capacity, infrastructure, and Shared Resources of the Cancer Center. CRR fosters excellence in basic science discovery in cancer biology; 28% of this Program’s papers were high-impact publications (journal impact factor >10). These discoveries directly led to six new investigator-initiated trials in the current funding period. Program Leaders facilitate meaningful, productive, interdisciplinary collaborations to achieve the goal of discovering and exploiting new mechanisms that underlie tumorigenesis and metastasis. Our success in collaborative intra- and inter-programmatic science is underscored by successful competition for nine new multi-principal investigator grants in the current funding period.

细胞反应和调节程序抽象的细胞反应与调节 (CRR) 项目是亨斯曼癌症研究所的一项基础科学项目 (HCI)，CRR 发现科学支持该中心“从根源上了解癌症”的使命。获得对癌症生物学基本机制的新见解，并为关键解决奠定基础 CRR 成员利用科学的独创性和广泛的经验来解决临床问题。 HCI 提供共享资源以做出新发现，并与 HCI 成员合作癌症控制和人口科学计划以及实验治疗计划翻译这些发现在癌症预防、靶点识别、生物标志物等领域为临床和人群带来了好处 CRR 研究的重点是以下方面。具体目标：1) 阐明细胞增殖、分化和存活的机制；2) 揭示介导肿瘤转移的机制和途径；3) 了解肿瘤的发展和对治疗的反应。 CRR 由 37 名成员组成，代表 15 个学术部门和 4 所学校/学院犹他大学 CRR 成员资金充足，拥有 820 万美元的同行评审拨款，其中 300 万美元。 (33%) 来自 NCI，同行评审的资金组合的其余部分包括专注于细胞的资助。美国国立卫生研究院、国防部的癌症机制，Susan G. Komen 基金会和美国癌症协会的正式会员中有百分之九十三是当前的同行。在当前的资助周期中，CRR 成员发表了 266 项以癌症为重点的资助。论文；其中 14% 代表项目内合作，41% 来自项目间合作合作。 CRR 计划的协同目标创造了高产、协作和有影响力的研究组织能力、基础设施和共享资源增强的环境癌症中心。该计划的 28% 致力于促进癌症生物学基础科学发现的卓越发展；论文是高影响力出版物（期刊影响因子>10）。这些发现直接导致了六篇新论文的产生。项目负责人在当前资助期间发起的试验促进了有意义的、富有成效的、跨学科合作，以实现发现和利用新机制的目标我们在程序内和程序间科学合作方面的成功在于。突出表现是在当前资金中成功竞争九项新的多学科研究者资助时期。